Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by A. Massy, Z.
Right arrow Articles by Guijarro, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by A. Massy, Z.
Right arrow Articles by Guijarro, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1738-1741
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Statins: effects beyond cholesterol lowering

Ziad A. Massy1, and Carlos Guijarro2

1 Division of Nephrology, CH Beauvais and INSERM U 507, Necker Hospital, Paris, France and 2 Fundación Hospital Alcorcón, Madrid, Spain

Keywords: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors; cholesterol; statins

Introduction

Recent large-scale placebo-controlled clinical trials have established beyond doubt the benefits of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-Co A) reductase inhibitors (statins) in the primary and secondary prevention of coronary heart disease [1]. The role of hypercholesterolaemia in the pathogenesis of atherosclerosis is also well established and statins are the most powerful available agents to safely reduce blood cholesterol levels. However, the greater than expected success of statin therapy has raised the possibility that certain beneficial effects go beyond their ability to reduce circulating cholesterol levels [2]. For example, the clinical benefits of statin therapy appear disproportionate to the improvement in atherosclerotic lesions demonstrated in angiographic studies [3]. Therefore, statins may reduce cardiovascular events by mechanisms different from regression of coronary atherosclerosis. Second, the rate of clinical events in some trials in from treated groups was lower than expected from estimations based on Framingham equations using . . . [Full Text of this Article]

Statins and the control of cell number

Statins and thrombosis

Statins and inflammation

Statins and endothelial function

Statins and immunomodulation

Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Mauro Vieira Jr, E. Mantovani, L. Tavares Rodrigues, H. Delle, I. L. Noronha, C. K. Fujihara, and R. Zatz
Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1582 - 1591.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw
Biochemical risk markers: a novel area for better prediction of renal risk?
Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Trovati and F. Cavalot
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20.
[Abstract] [Full Text]